SCHEMBL19973034

SCHEMBL19973034

N=Cc1cccc2c1Cc1ccccc1-2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.49
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HTR7 P34969 1/20 0.40
HTR2B P41595 1/20 0.40
MAOA P21397 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
MIF P14174 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1610350 0.85 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL3952483 0.84 PNMT (0.52) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL6421463 0.84 PNMT (0.52) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL68230 0.81 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL1245608 0.81 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL499896 0.81 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL8359461 0.81 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL29882364 0.81 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL2177653 0.79 PNMT (0.51) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL1306760 0.79 PNMT (0.47) PNMTNPC1RAB9AHTR7HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220055993-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-02-24 US disclosed
EP-3658576-A1 ANTICANCER PEPTIDES IDP Discovery Pharma, S.L. (ES) 2020-06-03 EP disclosed
WO-2019020649-A1 ANTICANCER PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2019-01-31 WO disclosed
WO-2018053373-A1 USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS THE GENERAL HOSPITAL CORPORATION (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055993-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES MKI67, PCNA, VHL PNMT 2539/4885NPC1 122/4885RAB9A 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.